Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multi-Cohort Phase II Trial of Temozolomide and Atezolizumab for Subsequent Line Treatment for Small Cell Lung Cancer

NCT04919382 is registered in ClinicalTrials.gov with Dwight Owen as lead sponsor.

NCT NCT04919382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04919382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multi-Cohort Phase II Trial of Temozolomide and Atezolizumab for Subsequent Line Treatment for Small Cell Lung Cancer
Lead sponsor
Dwight Owen
Phase
Phase 2
Overall status
Recruiting
Start date
January 26, 2022
Completion date
December 30, 2028
Enrollment
56 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

extensive stage lung small cell carcinoma, metastatic lung small cell carcinoma, recurrent lung small cell carcinoma, stage iv lung cancer ajcc v8, stage iva lung cancer ajcc v8, stage ivb lung cancer ajcc v8